Page 108 - Read Online

Sen. Hepatoma Res 2018;4:37 I http://dx.doi.org/10.20517/2394-5079.2018.39 Page 7 of 7

clinicopathologic parameters, p53 expression, and patient survival. J Hepatol 2000;32:78-84.
23. Chae S, Jun HO, Lee EG, Yang SJ, Lee DC, Jung JK, Park KC, Yeom YI, Kim KW. Osteopontin splice variants differentially modulate the
migratory activity of hepatocellular carcinoma cell lines. Int J Oncol 2009;35:1409-16.
24. Koga H, Tsedensodnom O, Tomimaru Y, Walker EJ, Lee HC, Kim KM, Yano H, Wands JR, Kim M. Loss of the SxxSS motif in a human
T-cell factor-4 isoform confers hypoxia resistance to liver cancer: an oncogenic switch in Wnt signaling. PLoS One 2012;7:e39981.
25. Liu L, Xie S, Zhang C, Zhu F. Aberrant regulation of alternative pre-mRNA splicing in hepatocellular carcinoma. Crit Rev Eukaryot Gene
Expr 2014;24:133-49.
26. Lu X, Feng X, Man X, Yang G, Tang L, Du D, Zhang F, Yuan H, Huang Q, Zhang Z, Liu Y, Strand D, Chen Z. Aberrant splicing of Hugl-1
is associated with hepatocellular carcinoma progression. Clin Cancer Res 2009;15:3287-96.
27. Castillo J, Goni S, Latasa MU, Perugorria MJ, Calvo A, Muntane J, Bioulac-Sage P, Balabaud C, Prieto J, Avila MA, Berasain C.
Amphiregulin induces the alternative splicing of p73 into its oncogenic isoform DeltaEx2p73 in human hepatocellular tumors.
Gastroenterology 2009;137:1805-15.e1-4.
28. Stiewe T, Zimmermann S, Frilling A, Esche H, Putzer BM. Transactivation-deficient DeltaTA-p73 acts as an oncogene. Cancer Res
2002;62:3598-602.
29. Yea S, Narla G, Zhao X, Garg R, Tal-Kremer S, Hod E, Villanueva A, Loke J, Tarocchi M, Akita K, Shirasawa S, Sasazuki T, Martignetti
JA, Llovet JM, Friedman SL. Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in
hepatocellular carcinoma. Gastroenterology 2008;134:1521-31.
30. Danan-Gotthold M, Golan-Gerstl R, Eisenberg E, Meir K, Karni R, Levanon EY. Identification of recurrent regulated alternative splicing
events across human solid tumors. Nucleic Acids Res 2015;43:5130-44.
31. Zhou X, Li X, Cheng Y, Wu W, Xie Z, Xi Q, Han J, Wu G, Fang J, Feng Y. BCLAF1 and its splicing regulator SRSF10 regulate the
tumorigenic potential of colon cancer cells. Nat Commun 2014;5:4581.
32. Anczukow O, Akerman M, Clery A, Wu J, Shen C, Shirole NH, Raimer A, Sun S, Jensen MA, Hua Y, Allain FH, Krainer AR. SRSF1-
regulated alternative splicing in breast cancer. Mol Cell 2015;60:105-17.
33. Sen S, Talukdar I, Webster NJ. SRp20 and CUG-BP1 modulate insulin receptor exon 11 alternative splicing. Mol Cell Biol 2009;29:871-80.
34. Talukdar I, Sen S, Urbano R, Thompson J, Yates JR 3rd, Webster NJ. hnRNP A1 and hnRNP F modulate the alternative splicing of exon 11
of the insulin receptor gene. PLoS One 2011;6:e27869.
35. Webster NJG. Alternative RNA splicing in the pathogenesis of liver disease. Front Endocrinol (Lausanne) 2017;8:133.
36. Sen S, Langiewicz M, Jumaa H, Webster NJ. Deletion of serine/arginine-rich splicing factor 3 in hepatocytes predisposes to hepatocellular
carcinoma in mice. Hepatology 2015;61:171-83.
37. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, Mikaelyan A, Roberts LR, Demetris AJ, Sun Z, Nevens F, Roskams
T, Thorgeirsson SS. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med
2006;12:410-6.
38. Becker D, Sfakianakis I, Krupp M, Staib F, Gerhold-Ay A, Victor A, Binder H, Blettner M, Maass T, Thorgeirsson S, Galle PR, Teufel A.
Genetic signatures shared in embryonic liver development and liver cancer define prognostically relevant subgroups in HCC. Mol Cancer
2012;11:55.
39. Bhate A, Parker DJ, Bebee TW, Ahn J, Arif W, Rashan EH, Chorghade S, Chau A, Lee JH, Anakk S, Carstens RP, Xiao X, Kalsotra A.
ESRP2 controls an adult splicing programme in hepatocytes to support postnatal liver maturation. Nat Commun 2015;6:8768.
40. Elizalde M, Urtasun R, Azkona M, Latasa MU, Goni S, Garcia-Irigoyen O, Uriarte I, Segura V, Collantes M, Di Scala M, Lujambio A,
Prieto J, Avila MA, Berasain C. Splicing regulator SLU7 is essential for maintaining liver homeostasis. J Clin Invest 2014;124:2909-20.
41. Urtasun R, Elizalde M, Azkona M, Latasa MU, Garcia-Irigoyen O, Uriarte I, Fernandez-Barrena MG, Vicent S, Alonso MM, Muntane J,
Prieto J, Avila MA, Berasain C. Splicing regulator SLU7 preserves survival of hepatocellular carcinoma cells and other solid tumors via
oncogenic miR-17-92 cluster expression. Oncogene 2016;35:4719-29.
42. Sen S, Jumaa H, Webster NJ. Splicing factor SRSF3 is crucial for hepatocyte differentiation and metabolic function. Nat Commun
2013;4:1336.
43. Wu S, Du R, Gao C, Kang J, Wen J, Sun T. The role of XBP1s in the metastasis and prognosis of hepatocellular carcinoma. Biochem
Biophys Res Commun 2018;500:530-7.
44. Yuan JH, Liu XN, Wang TT, Pan W, Tao QF, Zhou WP, Wang F, Sun SH. The MBNL3 splicing factor promotes hepatocellular carcinoma
by increasing PXN expression through the alternative splicing of lncRNA-PXN-AS1. Nat Cell Biol 2017;19:820-32.
45. Lin KT, Shann YJ, Chau GY, Hsu CN, Huang CY. Identification of latent biomarkers in hepatocellular carcinoma by ultra-deep whole-
transcriptome sequencing. Oncogene 2014;33:4786-94.
46. Wood M, Yin H, McClorey G. Modulating the expression of disease genes with RNA-based therapy. PLoS Genet 2007;3:e109.
47. Havens MA, Hastings ML. Splice-switching antisense oligonucleotides as therapeutic drugs. Nucleic Acids Res 2016;44:6549-63.